Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.34 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.34 |
| ▸ | RGS12 | O14924 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5661987 | 0.86 | DGAT1 (0.36) | DGAT1MAPT | |
| SCHEMBL26917090 | 0.84 | DGAT1 (0.35) | DGAT1MAPT | |
| SCHEMBL3973414 | 0.83 | SMN1; SMN2 (0.35) | DGAT1MAPT | |
| SCHEMBL7082758 | 0.83 | DGAT1 (0.34) | DGAT1MAPT | |
| SCHEMBL19148821 | 0.83 | ALDH1A1 (0.34) | ALDH1A1KDM4EHPGDHSD17B10MAPT | |
| SCHEMBL3313603 | 0.82 | NPC1 (0.40) | DGAT1MAPT | |
| SCHEMBL8664242 | 0.82 | DGAT1 (0.34) | DGAT1MAPT | |
| SCHEMBL3973140 | 0.82 | DGAT1 (0.32) | DGAT1MAPT | |
| SCHEMBL5137788 | 0.81 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL4675474 | 0.80 | ALDH1A1 (0.40) | ALDH1A1KDM4EHPGDHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118613483-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-06-27 | — | — | US | disclosed |
| EP-3845538-B1 | DIHYDROIMIDAZOPYRAZINONE COMPOUND, COMPOSITION INCLUDING SAME, AND USE THEREOF | SHENZHEN TARGETRX INC (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20230234968-A1 | METHYL-SUBSTITUTED BENZOBISOXAZOLE COMPOUND AND USE THEREOF | TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230234968-A1 | METHYL-SUBSTITUTED BENZOBISOXAZOLE COMPOUND AND USE THEREOF | TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. (CN) | 2023-07-27 | — | — | US | disclosed |
| US-20230203057-A1 | FIVE-MEMBERED HETEROAROMATIC IMIDAZOLE COMPOUND AND USE THEREOF | HANGZHOU SCIWIND BIOSCIENCES CO., LTD (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230192652-A1 | PLXDC2 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023098852-A1 | CRYSTAL FORMS OF THIENOIMIDAZOLE COMPOUND AND PREPARATION METHOD THEREOF | HANGZHOU SCIWIND BIOSCIENCES CO., LTD. (CN) | 2023-06-08 | — | — | WO | disclosed |
| US-11597717-B2 | Substituted imidazoles as PLXDC2 ligands | LANDOS BIOPHARMA, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| EP-4118081-A1 | PLXDC2 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-01-18 | — | — | EP | disclosed |
| WO-2007124318-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124318-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124316-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124316-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249593-A1 | e.g. 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent | MUSK, CHUK, PNCK | DGAT1 3459/4885ALDH1A1 3686/4885KDM4E 1098/4885 |
| US-20070249649-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | DGAT1 3866/4885ALDH1A1 4832/4885KDM4E 1642/4885 |
| US-20230234968-A1 | METHYL-SUBSTITUTED BENZOBISOXAZOLE COMPOUND AND USE THEREOF | CYP11B2, CYP11B1, TPMT | DGAT1 4406/4885ALDH1A1 1062/4885KDM4E 362/4885 |
| US-20240208993-A1 | FIVE- AND SIX-MEMBERED COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | IRAK4, FLT3, IRAK2 | DGAT1 4608/4885ALDH1A1 3673/4885KDM4E 488/4885 |
| US-20230203057-A1 | FIVE-MEMBERED HETEROAROMATIC IMIDAZOLE COMPOUND AND USE THEREOF | GLP1R, GIPR, GPR119 | DGAT1 2483/4885ALDH1A1 1560/4885KDM4E 2923/4885 |
| US-20230192652-A1 | PLXDC2 LIGANDS | PLP2, PDCD1LG2, LCP2 | DGAT1 3251/4885ALDH1A1 3872/4885KDM4E 3914/4885 |
| US-11597717-B2 | Substituted imidazoles as PLXDC2 ligands | PLK2, PLEC, PLP2 | DGAT1 4720/4885ALDH1A1 3834/4885KDM4E 2042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.